146 related articles for article (PubMed ID: 30611837)
21. [With the Characteristics of Chronic Pain Patients, Can the Therapeutic Effect of Antidepressant Duloxetine be Predicted?].
Enomoto T; Sugita M; Katsuta Y; Hori N; Koh K; Saito R; Hasegawa R; Takahashi Y; Sugasawa Y; Yamaguchi K; Isek M; Inada E
Masui; 2016 Oct; 65(10):1005-1008. PubMed ID: 30358274
[TBL] [Abstract][Full Text] [Related]
22. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
Nelson JC
Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
[TBL] [Abstract][Full Text] [Related]
23. 5-HTT mRNA level as a potential biomarker of treatment response in patients with major depression in a clinical trial.
Kao WT; Chang CL; Lung FW
J Affect Disord; 2018 Oct; 238():597-608. PubMed ID: 29957477
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
Cowen PJ; Ogilvie AD; Gama J
Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
[TBL] [Abstract][Full Text] [Related]
25. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder.
Montejo AL; Perahia DG; Spann ME; Wang F; Walker DJ; Yang CR; Detke MJ
J Sex Med; 2011 Mar; 8(3):773-82. PubMed ID: 21091877
[TBL] [Abstract][Full Text] [Related]
26. Reduced serum VGF levels were reversed by antidepressant treatment in depressed patients.
Jiang H; Chen S; Lu N; Yue Y; Yin Y; Zhang Y; Jiang W; Liang J; Yuan Y
World J Biol Psychiatry; 2017 Dec; 18(8):586-591. PubMed ID: 28635540
[TBL] [Abstract][Full Text] [Related]
27. Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression.
Dreimüller N; Schlicht KF; Wagner S; Peetz D; Borysenko L; Hiemke C; Lieb K; Tadić A
Neuropharmacology; 2012 Jan; 62(1):264-9. PubMed ID: 21803060
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC
Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049
[TBL] [Abstract][Full Text] [Related]
29. Duloxetine Plasma Concentrations and Its Effectiveness in the Treatment of Nonorganic Chronic Pain in the Orofacial Region.
Kobayashi Y; Nagashima W; Tokura T; Yoshida K; Umemura E; Miyauchi T; Arao M; Ito M; Kimura H; Kurita K; Ozaki N
Clin Neuropharmacol; 2017; 40(4):163-168. PubMed ID: 28622208
[TBL] [Abstract][Full Text] [Related]
30. Plasma microRNA expression levels and their targeted pathways in patients with major depressive disorder who are responsive to duloxetine treatment.
Kim HK; Tyryshkin K; Elmi N; Dharsee M; Evans KR; Good J; Javadi M; McCormack S; Vaccarino AL; Zhang X; Andreazza AC; Feilotter H
J Psychiatr Res; 2019 Mar; 110():38-44. PubMed ID: 30580082
[TBL] [Abstract][Full Text] [Related]
31. Effects of Magnesium Oxide on the Serum Duloxetine Concentration and Antidepressant-Like Effects of Duloxetine in Rats.
Esumi S; Kitamura Y; Yokota-Kumasaki H; Ushio S; Yamada-Takemoto A; Nagai R; Ogawa A; Kawasaki Y; Sendo T
Biol Pharm Bull; 2018; 41(11):1727-1731. PubMed ID: 30381673
[TBL] [Abstract][Full Text] [Related]
32. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder.
Acharya N; Rosen AS; Polzer JP; D'Souza DN; Perahia DG; Cavazzoni PA; Baldessarini RJ
J Clin Psychopharmacol; 2006 Dec; 26(6):587-94. PubMed ID: 17110815
[TBL] [Abstract][Full Text] [Related]
33. Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.
Fiori LM; Lopez JP; Richard-Devantoy S; Berlim M; Chachamovich E; Jollant F; Foster J; Rotzinger S; Kennedy SH; Turecki G
Int J Neuropsychopharmacol; 2017 Aug; 20(8):619-623. PubMed ID: 28520926
[TBL] [Abstract][Full Text] [Related]
34. The Antidepressant Duloxetine Inhibits Platelet Function and Protects against Thrombosis.
Lozano PA; Alarabi AB; Garcia SE; Boakye ET; Kingbong HT; Naddour E; Villalobos-García D; Badejo P; El-Halawany MS; Khasawneh FT; Alshbool FZ
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269729
[TBL] [Abstract][Full Text] [Related]
35. Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study.
Hellerstein DJ; Hunnicutt-Ferguson K; Stewart JW; McGrath PJ; Keller S; Peterson BS; Chen Y
J Affect Disord; 2017 Mar; 210():258-264. PubMed ID: 28064115
[TBL] [Abstract][Full Text] [Related]
36. Duloxetine: a review of its use in the treatment of major depressive disorder.
Frampton JE; Plosker GL
CNS Drugs; 2007; 21(7):581-609. PubMed ID: 17579500
[TBL] [Abstract][Full Text] [Related]
37. Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study.
Lisinski A; Hieronymus F; Näslund J; Nilsson S; Eriksson E
Neuropsychopharmacology; 2020 Feb; 45(3):553-560. PubMed ID: 31521062
[TBL] [Abstract][Full Text] [Related]
38. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo.
Robinson M; Oakes TM; Raskin J; Liu P; Shoemaker S; Nelson JC
Am J Geriatr Psychiatry; 2014 Jan; 22(1):34-45. PubMed ID: 24314888
[TBL] [Abstract][Full Text] [Related]
39. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
40. NGF serum levels variations in major depressed patients receiving duloxetine.
Martino M; Rocchi G; Escelsior A; Contini P; Colicchio S; de Berardis D; Amore M; Fornaro P; Fornaro M
Psychoneuroendocrinology; 2013 Sep; 38(9):1824-8. PubMed ID: 23507186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
